Efficacy of liraglutide added to sodium‐glucose cotransporter‐2 inhibitors in type 2 diabetes, stratified by baseline characteristics: Post‐hoc analysis of LIRA‐ADD2SGLT2i

Abstract

The LIRA‐ADD2SGLT2i trial demonstrated that liraglutide\u2009+\u2009sodium‐glucose cotransporter‐2 inhibitors (SGLT2is)\u2009±\u2009metformin significantly improved glycaemic control (not body weight) versus placebo in adults with type 2 diabetes (T2D). This post‐hoc analysis assessed whether baseline characteristics influenced these findings.